Gaudium IVF IPO Details: Price Band, Key Dates, GMP & Subscription Guide

Gaudium IVF and Women Health Limited has launched its highly anticipated public issue, drawing significant attention from investors across India. The IPO opened on February 20, 2026 and will remain available for subscription until February 24, 2026, giving retail and institutional investors a key opportunity to participate in a company positioned in the fast-growing fertility and assisted reproductive healthcare segment.

The total issue size is approximately ₹165 crore, consisting of a fresh issue worth ₹90 crore and an offer for sale (OFS) worth ₹75 crore by existing shareholders. The company has set a price band at ₹75 to ₹79 per share, valuing Gaudium IVF at a pre-IPO market capitalization of around ₹575 crore at the upper end of the band.

The Gaudium IVF IPO follows a book-built process and is being led by Sarthi Capital Advisors as the book running lead manager, while Bigshare Services Pvt. Ltd. is acting as the registrar. Investors must apply for shares in a minimum lot size of 189 shares, which translates to a minimum investment of roughly ₹14,931 at the upper price band.

Subscription and Market Sentiment

On the first day of bidding, market interest has shown steady engagement. Grey market premium (GMP), which reflects unofficial market expectations for listing gains, has been indicating positive sentiment. As of the initial days of subscription, the GMP hovered around 11% to ₹12 per share, suggesting expectations of a modest listing pop.

Additionally, on February 19, 2026, just ahead of the IPO opening, the company secured ₹49.5 crore from anchor investors, with over 62 lakh shares allocated at the upper price band of ₹79 per share. This anchor allocation often sets an early benchmark of institutional confidence prior to the public bidding process.

Business and Growth Potential

Founded and promoted by Dr. Manika Khanna, Gaudium IVF is focused on fertility treatments and women’s healthcare services, including in-vitro fertilization (IVF), ICSI, IUI and other advanced assisted reproductive technologies. The company operates a hub-and-spoke healthcare delivery model, with seven full-service IVF hubs and 28 spoke clinics across India. This setup supports scalability and efficient delivery of clinical services to a broad patient base.

The business also sees international patient inflows, catering to clients from regions like the UK, USA, Canada, and several African countries. The company’s growth story, backed by strong revenue increases in recent fiscal years and rising demand for fertility services, has drawn interest from analysts and retail investors alike.

Use of IPO Proceeds

Net proceeds from the fresh issue will be primarily used to expand the company’s network by establishing new IVF centres across India, repay or pre-pay certain outstanding debts, and support general corporate purposes. Specifically, roughly ₹50 crore is earmarked for setting up new facilities and around ₹20 crore for debt servicing.

Allotment and Listing Timeline

Investors can expect the share allotment status to be finalised shortly after the closing date, with allotment expected on February 25, 2026, and shares likely to be credited to investors’ Demat accounts by February 26, 2026. The company’s shares are scheduled to debut on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on February 27, 2026, subject to final approvals.

Overall, the Gaudium IVF IPO has garnered interest for its niche position in reproductive healthcare, attractive valuation parameters, and potential growth runway, offering an intriguing entry point for investors looking to tap into the healthcare space.